Sergio A. Quezada
Impact in
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Immunology 58
- Immunotherapy and Immune Responses 38
- Immune Cell Function and Interaction 24
- T-cell and B-cell Immunology 23
- Immune cells in cancer 6
- Oncology 57
- Cancer Immunotherapy and Biomarkers 39
- CAR-T cell therapy research 26
- Co-authors
- Karl S. Peggs (33 shared papers)James P. Allison (10 shared papers)Charles Swanton (23 shared papers)Randolph J. Noelle (9 shared papers)Elizabeth M. Jaffee (2 shared papers)Tyler R. Simpson (5 shared papers)Mark Yarchoan (1 shared paper)Solange Peters (1 shared paper)
- Journals
- Annals of Oncology (8 papers)Blood (7 papers)Cancer Research (7 papers)Nature Communications (6 papers)The Journal of Experimental Medicine (5 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Sergio A. Quezada
96 papers receiving 12.7k citations
Sergio A. Quezada's Hit Papers
Peers
Comparison fields: 5 of 123
- Immunology 6.9k
- Oncology 6.8k
- Cancer Research 1.3k
- Pulmonary and Respiratory Medicine 1.4k
- Molecular Biology 2.6k
Countries citing papers authored by Sergio A. Quezada
This map shows the geographic impact of Sergio A. Quezada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio A. Quezada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio A. Quezada more than expected).
Fields of papers citing papers by Sergio A. Quezada
This network shows the impact of papers produced by Sergio A. Quezada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio A. Quezada. The network helps show where Sergio A. Quezada may publish in the future.
Co-authors
The 25 scholars most cited alongside Sergio A. Quezada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic Hit paper breakdown → | 2018 | 1878 |
| 2 | Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma Hit paper breakdown → | 2013 | 1110 |
| 3 | Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity Hit paper breakdown → | 2015 | 845 |
| 4 | Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies Hit paper breakdown → | 2009 | 731 |
| 5 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis Hit paper breakdown → | 2017 | 676 |
| 6 | Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism Hit paper breakdown → | 2005 | 664 |
| 7 | Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts Hit paper breakdown → | 2010 | 645 |
| 8 | CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells Hit paper breakdown → | 2006 | 555 |
| 9 | CD40/CD154 Interactions at the Interface of Tolerance and Immunity Hit paper breakdown → | 2004 | 517 |
| 10 | Principles and use of anti-CTLA4 antibody in human cancer immunotherapy Hit paper breakdown → | 2006 | 338 |
| 11 | 2014 | 307 | |
| 12 | Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy Hit paper breakdown → | 2014 | 235 |
| 13 | Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma Hit paper breakdown → | 2021 | 229 |
| 14 | 2016 | 222 | |
| 15 | 2011 | 203 | |
| 16 | 2018 | 199 | |
| 17 | 2017 | 184 | |
| 18 | 2008 | 182 | |
| 19 | 2010 | 176 | |
| 20 | 2008 | 173 |
About Sergio A. Quezada
Sergio A. Quezada is a scholar working on Immunology, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 99 papers that have together received 12.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (39 papers), Immunotherapy and Immune Responses (38 papers), CAR-T cell therapy research (26 papers), Immune Cell Function and Interaction (24 papers), T-cell and B-cell Immunology (23 papers), Cancer Genomics and Diagnostics (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune cells in cancer (6 papers). The work is most often cited by research in Immunology (6.9k citations), Oncology (6.8k citations), Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (1.4k citations) and Molecular Biology (2.6k citations). Sergio A. Quezada has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Karl S. Peggs, James P. Allison, Charles Swanton, Randolph J. Noelle, Elizabeth M. Jaffee, Tyler R. Simpson, Mark Yarchoan, Solange Peters, Albrecht Stenzinger and Timothy A. Chan. Their work appears in journals such as Annals of Oncology, Blood, Cancer Research, Nature Communications and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.